A new preclinical study published in Nature Communications reports a tailored nanomedicine strategy aimed at treating hyperuricemia and its downstream complications in mice. The work centers on a delivery system that transports a circular RNA (circRNA) encoding secretory uricase, a strategy designed to enhance uric acid breakdown while potentially reducing inflammatory damage associated with elevated urate levels.
The researchers engineered “antioxidant malic-acid–derived lipid nanoparticles,” building the core chemistry around malate-linked components. This choice matters because hyperuricemia is frequently accompanied by oxidative stress, and the nanoparticle composition is intended to provide antioxidant activity in parallel with therapeutic delivery.
For cargo, the team used secretory uricase circRNA. Unlike linear RNA approaches, circRNAs are generally more resistant to nuclease degradation, which can translate to more sustained expression in vivo. The study’s central hypothesis is that a more durable circRNA signal, paired with antioxidant lipid formulation, could improve both efficacy and tolerability.
To evaluate delivery performance, the authors investigated how efficiently the nanoparticles entered target cells and how robustly they drove uricase production. Secreted uricase activity served as a functional readout, linking molecular delivery to biochemical outcomes relevant to urate metabolism.
In mouse experiments modeling hyperuricemia, treatment led to lower uric acid levels compared with controls, consistent with the restored enzymatic degradation of urate. Importantly, the study also assessed complication-associated endpoints, extending beyond serum chemistry to examine tissue responses linked to inflammation and oxidative injury.
The nanoparticle’s antioxidant design was reported to contribute to improved cellular stress markers, suggesting that the therapeutic effect was not solely dependent on uricase expression. This dual mechanism—biologic conversion of urate plus mitigation of oxidative pathways—forms the conceptual backbone of the approach.
Safety and tolerability were evaluated using standard preclinical observations and biomarker profiling. While detailed clinical translation remains ahead, the reported results point to a feasible formulation capable of sustained functional delivery.
Overall, the findings position malate-derived, antioxidant lipid nanoparticles as a promising platform for circRNA-based enzyme replacement. If future studies confirm long-term efficacy and safety, this approach could broaden the toolkit for precision RNA therapeutics in metabolic disease.
Subject of Research: Hyperuricemia; circRNA delivery; secretory uricase; antioxidant nanoparticle therapy
Article Title: Antioxidant malic-acid-derived lipid nanoparticles delivering secretory uricase circRNA for hyperuricemia and complication management in mice.
Article References: Du, K., Guo, Y., Zhou, J. et al. Antioxidant malic-acid-derived lipid nanoparticles delivering secretory uricase circRNA for hyperuricemia and complication management in mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73544-9
Image Credits: AI Generated
Tags: antioxidant lipid nanoparticles for nucleic acid deliverycircular RNA uricase therapy in micemalic-acid–derived lipid nanoparticles for therapeutic applicationsnanomedicine for oxidative stress in hyperuricemiaNanoparticle-mediated circRNA delivery for hyperuricemia treatmentnanotechnology-based treatment for uric acid reductionoxidative stress mitigation in hyperuricemia via nanomedicinesustained circRNA expression in vivo using lipid nanoparticlestargeted nanocarrier system for uricase enzyme delivery
